Frontline immunotherapy and immune cold reprogramming across molecular subtypes of advanced endometrial cancer
Open Access
- 4 June 2026
- journal article
- review article
- Published by Elsevier in Cancer Letters
- Vol. 655, 218652
Abstract
No abstract availableKeywords
Funding Information
- National Science and Technology Council (114-2628-B075B-001-MY3)
- National Science and Technology Council
- Kaohsiung Veterans General Hospital (115-052)
- Kaohsiung Veterans General Hospital (-082)
This publication has 116 references indexed in Scilit:
- Real-world safety and efficacy of immune checkpoint inhibitors in Japanese patients with persistent, recurrent, or metastatic cervical cancer: a multicenter prospective and retrospective studyInternational Journal of Clinical Oncology, 2026
- Immune checkpoint inhibitors in gynecologic oncology: Current status and perspectivesInternational Journal of Gynecology & Obstetrics, 2025
- Microsatellite instability-high status as a pan-cancer biomarker for immunotherapy efficacyCancer Immunology, Immunotherapy, 2025
- Lenvatinib enhances antitumor immunity of anti-PD-1 antibodyInternational Journal of Clinical Oncology, 2025
- Negative association of steroids with immunotherapy efficacy in a multi-tumor cohort: time and dose-dependentCancer Immunology, Immunotherapy, 2024
- FIGO staging of endometrial cancer: 2023International Journal of Gynecology & Obstetrics, 2023
- Dual Programmed Death Receptor‐1 and Vascular Endothelial Growth Factor Receptor‐2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular CarcinomaHepatology, 2019
- PD-1/PD-L1 blockade in cancer treatment: perspectives and issuesInternational Journal of Clinical Oncology, 2016
- Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1JAMA Oncology, 2015
- Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicinCancer Chemotherapy and Pharmacology, 2010